Patient Self-administration of Cortisol for Cortisol-responding Disorders in Men and Women Over the Age of 17
| Status: | Completed |
|---|---|
| Conditions: | Rheumatology |
| Therapuetic Areas: | Rheumatology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/17/2018 |
| Start Date: | January 1, 2000 |
| End Date: | December 31, 2016 |
Patient Self-administration of Cortisol for Cortisol-responding Disorders in Men and Women Over the Age of 17, Demonstration of Double-blind Trial Results
Participants diagnosed as having fibromyalgia, osteoarthritis, and rheumatoid arthritis are
to be brought to a minimum symptom state using a 3-week period during which they are to
ingest modest doses of cortisol tablets with weekly lowered tapered doses. Thereafter, the
participants are to be taught to self-administer cortisol tablets on the as-needed basis to
maintain the minimum symptom state. For this, they are to ingest a smaller-dosage, 5-day
tapered regimen of cortisol tablets to quench each reoccurring exacerbation of the disease at
its earliest stage. Participants are limited to using less than the safe use limit of
cortisol per month and are required to include a minimum of 10 days per month during which no
cortisol was ingested.
to be brought to a minimum symptom state using a 3-week period during which they are to
ingest modest doses of cortisol tablets with weekly lowered tapered doses. Thereafter, the
participants are to be taught to self-administer cortisol tablets on the as-needed basis to
maintain the minimum symptom state. For this, they are to ingest a smaller-dosage, 5-day
tapered regimen of cortisol tablets to quench each reoccurring exacerbation of the disease at
its earliest stage. Participants are limited to using less than the safe use limit of
cortisol per month and are required to include a minimum of 10 days per month during which no
cortisol was ingested.
OBJECTIVE: To define why and demonstrate how patient self-administration of cortisol with
stress management eliminates chronic inflammation pain within fibromyalgia, osteoarthritis,
and rheumatoid arthritis.
METHODS: One thousand seventeen hundred and twenty (1,720) participants with chronic
inflammation-containing diseases, were brought to a minimum symptom state using
daily-administered cortisol tablets. Thereafter, participants used 5-day, small-dosage
cortisol regimens to quench subsequent disorder exacerbations to maintain the minimum symptom
state. Stressors as emotional traumas, infections, allergies, and injuries were minimized to
reduce cortisol consumption and participant discomfort. This protocol is compliant with
current United States Food and Drug Administration recommendations for cortisol use applied
to corticosteroid-responding disorders.
stress management eliminates chronic inflammation pain within fibromyalgia, osteoarthritis,
and rheumatoid arthritis.
METHODS: One thousand seventeen hundred and twenty (1,720) participants with chronic
inflammation-containing diseases, were brought to a minimum symptom state using
daily-administered cortisol tablets. Thereafter, participants used 5-day, small-dosage
cortisol regimens to quench subsequent disorder exacerbations to maintain the minimum symptom
state. Stressors as emotional traumas, infections, allergies, and injuries were minimized to
reduce cortisol consumption and participant discomfort. This protocol is compliant with
current United States Food and Drug Administration recommendations for cortisol use applied
to corticosteroid-responding disorders.
Inclusion Criteria:
Clinical diagnoses of fibromyalgia, osteoarthritis, or rheumatoid arthritis -
Exclusion Criteria:
Congestive heart failure, stomach ulceration, unstable diabetes, and bipolar disorder
We found this trial at
1
site
Click here to add this to my saved trials
